Similar Papers

Paper Title
Journal
Date
Author
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial (S47.005)
Patricia Pozo-Rosich ... Emily Mccusker
Neurology | VOL. 100
Patricia Pozo-Rosich, et. al.Patricia Pozo-Rosich ... Emily Mccusker
25 Apr 2023
Psychometric Evaluation of the Activity Impairment in Migraine-Diary (AIM-D) Using Data From a Phase 3 (PROGRESS) Clinical Trial in Patients With Chronic Migraine (P8-12.008)
Pranav Gandhi ... David Dodick
Neurology | VOL. 100
Pranav Gandhi, et. al.Pranav Gandhi ... David Dodick
25 Apr 2023
Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial (P12-12.001)
Stephanie Nahas ... Yingyi Liu
Neurology | VOL. 100
Stephanie Nahas, et. al.Stephanie Nahas ... Yingyi Liu
25 Apr 2023
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study (P10-12.010)
Robert Croop ... Christopher Jensen
Neurology | VOL. 100
Robert Croop, et. al.Robert Croop ... Christopher Jensen
25 Apr 2023
View more papers

More From: Neurology

Paper Title
Journal
Date
Author
Reader Response: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Calixto Machado
Neurology | VOL. -
Calixto MachadoCalixto Machado
28 Jan 2025
Brain Hypertrophy in Patients With Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis and Its Clinical Correlates
Richard Zubal ... Marian Galovic
Neurology | VOL. 104
Richard Zubal, et. al.Richard Zubal ... Marian Galovic
28 Jan 2025
Reader Response: Wall-Eyed Bilateral Internuclear Ophthalmoplegia Variant Syndrome Caused by Isolated Left Thalamic Infarction.
Eric R Eggenberger
Neurology | VOL. 104
Eric R EggenbergerEric R Eggenberger
28 Jan 2025
Editors' Note: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Aravind Ganesh ... Steven L Galetta
Neurology | VOL. -
Aravind Ganesh, et. al.Aravind Ganesh ... Steven L Galetta
28 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.